Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 0.79 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.79 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.79 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.74 |
| ▸ | BCHE | P06276 | 1/20 | 0.71 |
| ▸ | DRD2 | P14416 | 1/20 | 0.71 |
| ▸ | DRD1 | P21728 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29787915 | 1.00 | KDM4E (1.00) | KDM4EALDH1A1HSD17B10ALOX15LMNA | |
| SCHEMBL29202140 | 1.00 | KDM4E (1.00) | KDM4EALDH1A1HSD17B10ALOX15LMNA | |
| Methyl Coclaurine SCHEMBL29373409 | 0.93 | KDM4E (0.86) | KDM4EALDH1A1HSD17B10ALOX15LMNA | |
| SCHEMBL12807694 | 0.93 | KDM4E (0.86) | KDM4EALDH1A1HSD17B10ALOX15LMNA | |
| Methyl Coclaurine SCHEMBL12807819 | 0.93 | KDM4E (0.86) | KDM4EALDH1A1HSD17B10ALOX15LMNA | |
| Methyl Coclaurine SCHEMBL18179206 | 0.93 | KDM4E (0.86) | KDM4EALDH1A1HSD17B10ALOX15LMNA | |
| Methyl Coclaurine SCHEMBL1627504 | 0.93 | KDM4E (0.86) | KDM4EALDH1A1HSD17B10ALOX15LMNA | |
| Methyl Coclaurine SCHEMBL29365454 | 0.93 | KDM4E (0.86) | KDM4EALDH1A1HSD17B10ALOX15LMNA | |
| SCHEMBL18468569 | 0.91 | KDM4E (0.83) | KDM4EALDH1A1HSD17B10ALOX15LMNA | |
| SCHEMBL29846272 | 0.91 | KDM4E (0.83) | KDM4EALDH1A1HSD17B10ALOX15LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 156 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4267138-A1 | PRODRUGS OF PHARMACEUTICAL AGENTS | Axelyf ehf. (IS) | 2023-11-01 | — | — | EP | claimed |
| CN-116376863-A | Plumula Nelumbinis O-methyltransferase and application of encoding gene thereof in biosynthesis of single/double benzyl isoquinoline alkaloid | 中国中医科学院中药研究所 | 2023-07-04 | — | — | CN | claimed |
| WO-2022140705-A1 | PRODRUGS OF PHARMACEUTICAL AGENTS | ALMARSSON ORN (US) | 2022-06-30 | — | — | WO | claimed |
| CN-105726640-A | Preparing method and application of high-purity lotus leaf total alkaloid extract | 中国药科大学 | 2016-07-06 | — | — | CN | claimed |
| EP-2305260-B1 | Psychotropic agent and health food containing benzylisoquinoline derivative | INST OF ORIENTAL MEDICAL SCIENCE INC (JP) | 2012-12-05 | — | — | EP | claimed |
| US-7799802-B2 | Method and health food for preventing and/or alleviating psychiatric disorder, and/or for effectuating sedation | Institstute of Oriental Medical Science Inc. (JP) | 2010-09-21 | — | — | US | claimed |
| CN-101085041-A | Total alkaloid of lotus leaves extraction and its preparation method | RENBING SHI (CN) | 2007-12-12 | — | — | CN | claimed |
| US-20250197356-A1 | METHOD FOR SYNTHESIZING NUCIFERINE OR DERIVATIVE THEREOF, DERIVATIVE OF NUCIFERINE AND USE THEREOF | HUAQIAO UNIVERSITY (CN) | 2025-06-19 | — | — | US | disclosed |
| US-12091696-B2 | O-methyltransferase protein with highly specific catalytic function for multiple bias parent nuclei and encoding gene and use thereof | INSTITUTE OF CHINESE MATERIA MEDICA CHINA ACADEMY OF CHINESE MEDICAL SCIENCES (CN) | 2024-09-17 | — | — | US | disclosed |
| CN-118477008-A | Application of 8 herbal tea compound extracts in preparation of skin care cosmetic composition | 康丽园股份公司 | 2024-08-13 | — | — | CN | disclosed |
| CN-114891840-B | Lotus leaf O-methyltransferase and application of encoding gene thereof in synthesis of benzyl isoquinoline alkaloid and phenylpropionic acid compounds | 中国中医科学院中药研究所 | 2024-04-30 | — | — | CN | disclosed |
| US-20240108733-A1 | PRODRUGS OF PHARMACEUTICAL AGENTS | ALMARSSON ORN (US) | 2024-04-04 | — | — | US | disclosed |
| US-20240052388-A1 | O-METHYLTRANSFERASE PROTEIN WITH HIGHLY SPECIFIC CATALYTIC FUNCTION FOR MULTIPLE BIAS PARENT NUCLEI AND ENCODING GENE AND USE THEREOF | INSTITUTE OF CHINESE MATERIA MEDICA CHINA ACADEMY OF CHINESE MEDICAL SCIENCES (CN) | 2024-02-15 | — | — | US | disclosed |
| US-20060030586-A1 | Method and health food for preventing and/or alleviating psychiatric disorder, and/or for effectuating sedation | EDUCATION CENTER OF TRADITIONAL CHINESE MEDICINE CO. (JP) | 2006-02-09 | — | — | US | disclosed |
| CN-1446577-A | Medicine combination for treating child fastidium | ZENG FANXUN (CN) | 2003-10-08 | — | — | CN | disclosed |
| EP-0872903-B1 | Method for making hydrogen storage alloy powder and electrode comprising the alloy powder | SHINETSU CHEMICAL CO (JP) | 2001-10-04 | — | — | EP | disclosed |
| US-6277519-B1 | QUENCHING AN ALLOY MELT; COMMINUTION | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2001-08-21 | — | — | US | disclosed |
| CN-1253169-A | Lotus leaf extract, essential oil and preparation method thereof | LIN BO (CN) | 2000-05-17 | — | — | CN | disclosed |
| EP-0872903-A1 | Method for making hydrogen storage alloy powder and electrode comprising the alloy powder | Shin-Etsu Chemical Co., Ltd. (JP) | 1998-10-21 | — | — | EP | disclosed |
| CN-1166337-A | Weight-reducing tea | FANG DONGSHENG (CN) | 1997-12-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250197356-A1 | METHOD FOR SYNTHESIZING NUCIFERINE OR DERIVATIVE THEREOF, DERIVATIVE OF NUCIFERINE AND USE THEREOF | NUCB2, NISCH, CYP46A1 | KDM4E 2645/4885ALDH1A1 894/4885HSD17B10 125/4885 |
| US-20060030586-A1 | Method and health food for preventing and/or alleviating psychiatric disorder, and/or for effectuating sedation | GABRB1, GABRA1, GABRB2 | KDM4E 1467/4885ALDH1A1 791/4885HSD17B10 1202/4885 |
| US-20240108733-A1 | PRODRUGS OF PHARMACEUTICAL AGENTS | PAICS, UGT1A6, ENTPD5 | KDM4E 1917/4885ALDH1A1 808/4885HSD17B10 1038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.